Literature DB >> 8564254

Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

S M Gardiner1, J E March, P A Kemp, J J Mullins, T Bennett.   

Abstract

1. Hypertensive transgenic (TGR(mRen-2)27) (abbreviated to TG) rats (n = 6) and their normotensive Sprague-Dawley (SD) control strain (n = 7) were chronically instrumented for the measurement of cardiac haemodynamics. The hypertension in TG rats (mean blood pressure 181 +/- 9 mmHg) was entirely attributable to a reduction in total peripheral conductance (TG rats = 169 +/- 7, SD rats = 292 +/- 15 microliters min-1 mmHg-1 100g-1) since cardiac index was not different in the two strains (TG rats = 30.5 +/- 1.2, SD rats = 29.5 +/- 1.6 ml min-1 100g-1). 2. In other animals instrumented for the assessment of regional haemodynamics, the extent of peripheral vasoconstriction was similar in renal, mesenteric and hindquarters vascular beds in the TG rats (reduction in vascular conductance relative to SD rats = 42%, 46% and 49%, respectively). 3. During an 8 h observation period with saline infusion, or following injection of losartan (10 mg kg-1) in SD rats there was no hypotension or regional vasodilation. With infusion of the endothelin antagonist, SB 209670 (10 micrograms kg-1 min-1), there was a slight hypotension, but no significant vasodilation; co-administration of losartan and SB 209670 caused a similar profile of effect, although the hypotension was increased. 4. With the same experimental protocol in TG rats, losartan caused a biphasic, progressive fall in mean arterial blood pressure accompanied by renal, mesenteric and hindquarters vasodilation. Although the response to SB 209670 was not biphasic, its hypotensive and vasodilator effects were not different from those of losartan after 8 h. In the combined presence of losartan and SB 209670, mean arterial blood pressure (116 +/- 5 mmHg) was significantly lower than with SB 209670 (132+/-4 mmHg) or losartan(136 +/- 6 mmHg) alone, and renal, mesenteric and hindquarters vascular conductances (61 +/- 3, 90+/-14 and 52+/-4 [kHz nmHg-1]103, respectively) were higher than the corresponding values following either SB 209670 (49 +/- 4, 52 +/- 4 and 34 +/- 3 [kHz mmHg- 1]103, respectively) or losartan (43 +/- 5, 59 +/- 13 and 35+/-4 [kHz mmHg-1]103, respectively) alone. These results indicate the maintenance of hypertension inTG rats is dependent upon renal, mesenteric and hindquarters vasoconstriction, mediated by angiotensinII (AII) and endothelin (ET). Since we found that plasma ET-1 levels in TG rats (12.06+/-2.87 pmol 1-1)were lower than in SD rats (21.53 +/- 3.94 pmol 1-1), then it is possible that locally-generated, rather than circulating ET-l contributes to the widespread vasoconstriction in TG rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564254      PMCID: PMC1908969          DOI: 10.1111/j.1476-5381.1995.tb15059.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.

Authors:  T D Warner; G H Allcock; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

2.  Renal effects of captopril and nitrendipine in transgenic rats with an extra renin gene.

Authors:  C Hirth-Dietrich; J P Stasch; D Ganten; F C Luft
Journal:  Hypertension       Date:  1994-05       Impact factor: 10.190

3.  Beta-adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats.

Authors:  M Böhm; M Moll; B Schmid; M Paul; D Ganten; M Castellano; E Erdmann
Journal:  Hypertension       Date:  1994-12       Impact factor: 10.190

4.  Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats.

Authors:  E H Ohlstein; S A Douglas; M Ezekiel; M Gellai
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

5.  SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.

Authors:  E H Ohlstein; P Nambi; S A Douglas; R M Edwards; M Gellai; A Lago; J D Leber; R D Cousins; A Gao; J S Frazee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension.

Authors:  S A Douglas; M Gellai; M Ezekiel; E H Ohlstein
Journal:  J Hypertens       Date:  1994-05       Impact factor: 4.844

7.  Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670.

Authors:  S A Douglas; M Gellai; M Ezekiel; G Z Feuerstein; J D Elliott; E H Ohlstein
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

8.  Myocardial remodeling in hypertensive Ren-2 transgenic rats.

Authors:  F J Villarreal; D A MacKenna; J H Omens; W H Dillmann
Journal:  Hypertension       Date:  1995-01       Impact factor: 10.190

9.  Antihypertensive effects of BQ-123, a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt.

Authors:  M Okada; T Fukuroda; K Shimamoto; R Takahashi; F Ikemoto; M Yano; M Nishikibe
Journal:  Eur J Pharmacol       Date:  1994-07-11       Impact factor: 4.432

10.  In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.

Authors:  S A Douglas; R M Edwards; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more
  9 in total

1.  Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Endothelin mediates some of the renal actions of acutely administered angiotensin II.

Authors:  A Riggleman; J Harvey; C Baylis
Journal:  Hypertension       Date:  2001-07       Impact factor: 10.190

3.  Cardiovascular responses to angiotensins I and II in normotensive and hypertensive rats; effects of NO synthase inhibition or ET receptor antagonism.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

5.  Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats.

Authors:  V Niranjan; S Télémaque; D deWit; R D Gerard; M Yanagisawa
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

7.  Endothelin as a causative factor of blunted volume reflex in diabetic rats.

Authors:  Orawan Wongmekiat; Edward J Johns
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

8.  Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

9.  TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Authors:  Anookh Mohanan; Ram Gupta; Amita Dubey; Vikrant Jagtap; Appaji Mandhare; Ramesh C Gupta; Vijay Chauthaiwale; Chaitanya Dutt
Journal:  Int J Hypertens       Date:  2011-12-22       Impact factor: 2.420

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.